Building upon these findings, targeted therapies combining anti-PD-1 checkpoint blockers with hypomethylating agents may offer enhanced efficiency in AITL treatment, while potentially reducing toxicity compared to standard chemotherapy. The gene discussed is PDCD1; the disease is angioimmunoblastic T-cell lymphoma.